On March 18, 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the company and its research collaborators will present 28 abstracts, including 3 oral sessions, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, California taking place April 17 – 22, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key data that will be presented include:
An oral presentation of research data showing high accuracy of Guardant360 Tissue in determining tissue of origin with strong performance in cancers of unknown primary, correctly identifying the likely origin in approximately 92% of known cases across more than 6,000 tissue samples and 24 tumor types and supporting the clinical utility of methylation-based tumor typing for tissue samples in diagnostically challenging settings.
An oral presentation showcasing the expanded utility of Guardant360 Liquid beyond basic genomic testing, highlighting the strength of its novel epigenomic features in increasing clinical actionability. Researchers found that Guardant360 Liquid demonstrated actionable findings for 85% of metastatic breast cancer patients and 89% of patients with advanced colorectal cancer.
A real-world analysis evaluating the utility of Guardant Reveal to identify new primary malignancies during minimal residual disease (MRD) monitoring, demonstrating the potential to detect separate primary cancers in patients over time with non-invasive, liquid biopsy technology.
Additional research bolstering the potential of Guardant360 Tissue in expanding access to targeted treatment options showing that a tissue-based genomic instability score (GIS) can accurately detect DNA repair deficiencies in breast, ovarian, and pancreatic cancers and accurately identifying patients who may benefit from PARP inhibitors.
"The breadth of the data Guardant will be presenting demonstrate the power of our blood- and tissue-based tests in helping address critical gaps across cancer care," said Dr. Craig Eagle, Chief Medical Officer at Guardant Health. "From identifying cancers of unknown primary and detecting new malignancies in tandem with MRD monitoring to expanding treatment options for more cancers, we are eager to present these findings along with our research collaborators at the AACR (Free AACR Whitepaper) meeting and proud to offer innovative tests that are meeting today’s most complex challenges in cancer care."
Key Guardant Health and collaborator presentations at AACR (Free AACR Whitepaper) 2026
Presentation
Title
Time / Location
Monday, April 19
1316
A methylation-based molecular tumor typing classifier for tissue samples from cancers of unknown primary
April 19, 2026 / 3:00 PM – 5:00 PM PT
Tuesday, April 20
4016
Tissue-based homologous recombination deficiency status prediction in patients with breast, ovarian, and pancreatic cancers
April 20, 2026 / 2:30 PM – 4:30 PM PT
2279
DNA methylation-based classifier predicts SERD benefit in ESR1 wild-type HR+/HER2- breast cancer
April 20, 2026 / 9:00 AM – 12:00 PM PT
Poster hall / Section 34
Wednesday, April 21
6512
Exploring clinical actionability of expanded liquid biopsy in advanced breast and colorectal cancers
April 21, 2026 / 2:00 PM – 5:00 PM PT
Poster Section 43
6512
Evaluating molecular tumor type predictions for identifying new primary malignancies – A real-world clinical genomics analysis
April 21, 2026 / 2:00 PM – 5:00 PM PT
Poster Section 43
CT230
STRIDE regimen of tremelimumab and durvalumab as non-operative management strategy of MSI-H resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): final results of the cohort 2 of INFINITY study by GONO GI
April 21, 2026 / 10:15 AM – 12:15 PM PT
The full abstracts for Guardant Health and a list of all abstracts being presented at the AACR (Free AACR Whitepaper) Annual Meeting can be found here.
About Guardant360
Guardant360 Liquid is a blood-based test that analyzes tumor DNA fragments circulating in the blood (cfDNA) to identify genetic mutations in advanced solid tumors, helping oncologists find targeted therapies. It offers an alternative to tissue biopsies, providing comprehensive genomic profiling (CGP) to guide personalized treatment for a wide range of solid cancers including lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is guideline-complete across all advanced solid tumors, and has been clinically validated in more than 1,500 publications and research abstracts.
About Guardant Reveal
Guardant Reveal is a tissue-free liquid biopsy test that detects minimal residual disease (MRD) and monitors recurrence in early-stage colorectal, breast, and lung cancers, helping oncologists guide treatment decisions. In addition to MRD detection, Reveal can be used for late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights.
The first clinical-validation study of pan-cancer chemotherapy monitoring published in The Journal of Liquid Biopsy showed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.
(Press release, Guardant Health, MAR 18, 2026, View Source [SID1234663721])